TRVI

Trevi Therapeutics Stock Price

5.56
-1.42 (-20.34%)
Upgrade to Real-Time
Regular Market
5.56
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Trevi Therapeutics Inc TRVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-1.42 -20.34% 5.56 5.068 7.1207 7.04 6.98 15:42:34
Bid Price Ask Price Spread Spread % News
5.40 5.56 0.16 2.88% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
793 170,488 $ 5.90 $ 1,005,724 130,206 1.33 - 8.49
Last Trade Time Type Quantity Stock Price Currency
15:42:34 185 $ 5.56 USD

Trevi Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 99.92M 17.84M 5.03M $ - $ - -1.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 10.00 5.50%

more financials information »

Trevi Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TRVI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week7.048.495.0686.9284,074-1.48-21.02%
1 Month4.218.493.705.6583,1691.3532.07%
3 Months2.908.492.504.0983,4352.6691.72%
6 Months4.468.491.333.6571,8351.1024.66%
1 Year7.738.491.333.7641,823-2.17-28.07%
3 Years9.5010.621.335.1450,563-3.94-41.47%
5 Years9.5010.621.335.1450,563-3.94-41.47%

Trevi Therapeutics Description

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.


Your Recent History
NASDAQ
TRVI
Trevi Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.